Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study
Frontiers in Immunology · 15.05.2025 · 16
DOI: 10.3389/fimmu.2025.1591771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 15.05.2025. Verfasst von Fangfang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Encephalitis, Autoantibodies, Hashimoto Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The aims of the study were to characterize the clinical manifestations and outcomes of patients with antibody-negative severe autoimmune encephalitis (AE).
Methods
This retrospective, monocentric study recruited patients from the Neurology Department of Henan Provincial People’s Hospital between April 2017 and December 2023. All patients underwent neural antibody testing in both blood and cerebrospinal fluid (CSF) and met the diagnostic criteria for autoantibody-negative but probable severe AE, with available 1-year follow-up data.
Results
In total, 124 patients with autoantibody-negative severe AE were analyzed. Among them, 27.4% achieved good functional outcomes at discharge. Older age (OR 1.034, 95% confidence interval [CI] 1.010-1.058, p = 0.004) and the presence of dyskinesia/dystonia (OR 8.463, 95% CI 3.282-21.820, p < 0.001) were predictive of poor short-term outcomes. At the 1-year follow-up, 54.8% experienced favorable long-term outcomes. Independent predictors of unfavorable long-term outcomes included older age (OR 1.076, 95% CI 1.018-1.136, p = 0.009), longer hospital stays (OR 1.264, 95% CI 1.105-1.446, p = 0.001), the presence of refractory status epilepticus (OR 14.765, 95% CI 1.759-123.935, p = 0.013) and higher CASE scores at discharge (OR 2.079, 95% CI 1.450-2.980, p < 0.001). Additionally, 30.6% of patients had relapsed, with refractory status epilepticus being an independent risk factor for relapse.
Conclusion
Although patients with antibody-negative severe AE experience significant disability in the early stages of their disease, the majority eventually regain independent functioning. Older age at disease onset, longer hospital stays, the presence of refractory status epilepticus and higher CASE scores at discharge may predict a poor long-term prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
- Department of Neurology, Henan University People's Hospital, Zhengzhou, China.
- The Second Affiliated Hospital of Luohe Medical College, Luohe, Henan, China.
Zitieren
APA
Li, F., He, Y., Chen, X., Yang, A., Zhang, J., & Zang, W. (2025). Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1591771
Vancouver
Li F, He Y, Chen X, Yang A, Zhang J, Zang W. Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1591771
BibTeX
@article{Li2025,
author = {Li, Fangfang and He, Yu and Chen, Xiaoqian and Yang, Ali and Zhang, Jiewen and Zang, Weizhou},
title = {Clinical spectrum and long-term outcomes of antibody-negative severe autoimmune encephalitis: a retrospective study},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1591771}
}
EUVIMED